Pay to Marwadi

Company Profile

SOLARA ACTIVE PHARMA SCIENCES LTD.

NSE : SOLARABSE : 541540ISIN CODE : INE624Z01016Industry : Pharmaceuticals & DrugsHouse : Private
BSE533.955.5 (+1.04 % )
PREV CLOSE (Rs.) 528.45
OPEN PRICE (Rs.) 523.15
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 28917
TODAY'S LOW / HIGH (Rs.)523.15 549.50
52 WK LOW / HIGH (Rs.)287 606.95
NSE532.65 5 (+0.95 % )
PREV CLOSE(Rs.) 527.65
OPEN PRICE (Rs.) 528.40
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 532.65 (664 )
VOLUME 192385
TODAY'S LOW / HIGH(Rs.) 527.65 547.00
52 WK LOW / HIGH (Rs.)286 606.4

Company Profile

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.00
TTM EPS (Rs.) -84.46
P/E Ratio 0.00
Book Value (Rs.) 331.31
Face Value (Rs.) 10
MCap (Rs. in Mn) 19220.21
Price/Earning (TTM) -9.63
Price/Sales (TTM) 1.37
Price/Book (MRQ) 1.61
PAT Margin (%) -1.54
ROCE (%) 1.79
Incorporation Year : 2017

Management Info :

- Chairman Poorvank Purohit - Managing Director

Registered Office :

Address : 201, Devavrata,Sector 17,Vashi,
Navi Mumbai,
Maharashtra-400703

Phone : 022 2789 2924 / 2789 3199

Website : www.solara.co.in

Registrar's Details : Cameo Corporate Services Ltd
Subramanian Buildings No 1 ,Club House Road,,Chennai
Listing : BSE, NSE
NEWS More
26Apr04-26-2024$Solara Active Pharma Sciences sells 100% stake in SeQuent Penems Solara Active Pharma Science

Solara Active Pharma Sciences has completed sale of 100% shareholding in SeQuent Penems to M/s. Symbio Generrics India on April 25, 2024. Hence, SeQuent Penems ceased to be a subsidiary of the Company. The board of directors of the company at its meeting held on March 25, 2024 approved the same.  

Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer.

Solara Active Pharma Sciences has completed sale of 100% shareh..
22Apr04-22-2024$ Clarification sought from Solara Active Pharma Sciences Ltd Clarification sought from S
The Exchange has sought clarification from Solara Active Pharma Sciences Ltd on April 22, 2024 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded. The reply is awaited.
The Exchange has sought clarification from Solara Active Pharma..
26Mar03-26-2024$Solara Active Pharma Sciences gets nod to sell 100% stake in SeQuent Penems Solara Active Pharma Science

Solara Active Pharma Sciences has received approval from board of directors to sell 100% shareholding in SeQuent Penems. The board of directors of the company at its meeting held on March 25, 2024 approved the same.  

Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer.

Solara Active Pharma Sciences has received approval from board..
08Mar03-08-2024$Solara Active Pharma Sciences informs about appointment of CFO Solara Active Pharma Science
Solara Active Pharma Sciences has informed that the Board in its meeting held today approved the appointment of Arun Kumar Baskaran as Chief Financial Officer (CFO) of the Company and designated him as Key Managerial Personnel with effective from March 8, 2024. The details required under Regulation 30 of the Listing Regulations are attached herewith as Annexure –‘A’ In terms of Regulation 30(5) of the Listing Regulations, Arun Kumar Baskaran is also authorized to determine materiality of an event or information for the purpose of making disclosures relating to the Company to the Stock Exchanges.

The above information is a part of company’s filings submitted to BSE.

Solara Active Pharma Sciences has informed that the Board in it..
08Mar03-08-2024$Solara Active Pharma Sciences informs about notice of postal ballot Solara Active Pharma Science
Pursuant to Section 110 of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014, Solara Active Pharma Sciences has informed that it is proposed to transact the following business by way of postal ballot; Approval for appointment of Mohan Muthunarayanan (DIN: 03610282) as an Executive Director of the Company (Special Resolution). Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it has enclosed the notice of the Postal Ballot dated February 14, 2024, as sent to the Members on their registered Email address.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Section 110 of the Companies Act, 2013 read with th..
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit-2753.3-222.099999999999
Gross Profit -2753.3 -447.799999999999
Operating Profit -1612.31561.8
Net Sales 2487.314438.1
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Neuland Laboratories (BSE)
 7600.75 (5.52%)
M.Cap ( in Cr)
9751.68
Procter&Gamble Healt (BSE)
 4916.35 (2.97%)
M.Cap ( in Cr)
8160.84
Abbott India (BSE)
 26415.75 (0.53%)
M.Cap ( in Cr)
56131.62
Pfizer (BSE)
 4253.30 (1.13%)
M.Cap ( in Cr)
19457.88
Sanofi India (BSE)
 8324.10 (0.51%)
M.Cap ( in Cr)
19170.92
Shareholding Pattern More
NON-INSTITUTION 50.74 %
PROMOTERS 30.49 %
MUTUAL FUNDS/UTI 1.71 %
FI/BANKS/INSURANCE 0.04 %
GOVERNMENT 0 %
FII 0 %
MF HOLDINGS More
F & O Quotes